Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation

Key Takeaway: Eledon Pharmaceuticals has announced promising initial data regarding Tegoprubart, which is being tested in subjects with Type 1 diabetes as part of an immunosuppression regimen following islet transplantation. The results indicate positive outcomes, suggesting the drug's potential effectiveness in this patient population. This development could significantly impact treatment strategies for Type 1 diabetes.
Price reaction · baseline $2.62 (2024-10-04 close) · 5 other ELDN headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Initial data shows positive outcomes for Type 1 diabetes patients.
  • Tegoprubart demonstrates potential in immunosuppression post-islet transplantation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is Tegoprubart used for?

Tegoprubart is being tested for its potential in treating Type 1 diabetes.

What were the results of the initial data?

The initial data showed positive outcomes for patients with Type 1 diabetes.

How does Tegoprubart relate to islet transplantation?

Tegoprubart is part of an immunosuppression regimen following islet transplantation.

Who announced the positive data?

Eledon Pharmaceuticals announced the positive initial data.

Last updated: Oct 6, 2024